In recent market action, marijuana stocks have started to see a small rise in trading. This could be due to a few reasons, one of which may be working through an uncertain time. Investors could be taking market action, buying and selling, and causing more speculation that signals now could be a safe window to trade. So far, no major changes have taken place for most legal operators in the US.
According to the Internal Revenue Service (IRS), passive income generally includes earnings from rental activity or any trade, business, or investment in which the individual does not materially participate.
Genuine Parts benefits from tariffs, which make new cars less attractive and boost demand for replacement parts. 63% of sales come from this segment. The company's industrial segment could also benefit from onshoring. The company is investing in cost-saving technologies and projects $200 million in annualized savings by 2026. Despite market pessimism, GPC's attractive valuation and strong dividend coverage make it a compelling buy on a 12-month view.
Wall Street logged the best week since 2023 despite tariff turmoil and wild market swings. Rate-hedged ETFs, gold and silver miners and semiconductors led the weekly gains.
Investors have been waiting for energy stocks to find their sweet spot. And the same can be said for oil and gas companies when it comes to the price of oil.
Fear and uncertainty have dominated the markets in 2025, with U.S. equities entering a significant correction. What began as a cautious retreat in February, sparked by policy concerns and underwhelming performance from former market leaders and Magnificent Seven stocks, like Tesla and Alphabet, has now escalated into broader selling pressure.
First Solar stands to benefit from US reindustrialization policies, despite potential tax credit cutbacks under the current administration. FSLR's mixed 4Q24 results were impacted by warranty charges and production issues, but management expects strong growth in 2025. Section 45X tax credits are crucial for FSLR's profitability. I believe potential cutbacks are unlikely, given the current administration's focus on bringing back manufacturing to the US.
Shares of new artificial intelligence (AI) winners Marvell Technologies (MRVL 2.67%), Credo Technologies (CRDO 7.57%), and Nebius Group (NBIS 4.07%) plunged in March, down 32.9%, 27.2%, and 35%, respectively, according to data from S&P Global Market Intelligence.
Inverse and volatility ETFs won in the worst week of Wall Street since 2020.
With some pharmaceutical stocks paying 4% and higher dividends, they may be the perfect total return idea for the rest of 2025.
European ETFs amassed hefty assets in Q1 2025. Here's why.
Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 300% in Q1 2025 due to positive Phase 2b trial results for its lead drug candidate, neflamapimod despite earlier setbacks. Chimerix Inc. gained over 144% after announcing an acquisition by Jazz Pharmaceuticals and positive FDA feedback on its lead drug candidate, dordaviprone.